NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with ...

Definition: The Lipid-Lowering Agents market covers drugs to treat hyperlipidemia or dyslipidemia. These metabolic disorders are characterized by high levels of lipids, such as fats, cholesterol ...

Why isn’t lovastatin bringing down my cholesterol levels to normal? — S.A. ANSWER: Lovastatin (Mevacor) was the first statin drug approved, but newer statin drugs are more potent and have less ...

Why isn’t lovastatin bringing down my cholesterol levels to normal? S.A. Lovastatin (Mevacor) was the first statin drug approved, but newer statin drugs are more potent and have less likelihood ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs is associated with between 4 and 25 percent lower risk of dementia.

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced ... lowering medicines are not approved to lower Lp(a) levels in people living ...